

Claims:

1. Use of frankincense, frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiologically acceptable salts thereof, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative or a boswellic acid-containing vegetable preparation for the production of a medicament for the prophylactic and/or therapeutic treatment of cranial/brain trauma and/or cerebral ischemia.
2. Use according to claim 1, wherein the cerebral ischemia occurs as a result of apoplexy, cardiac infarction or an operation.
3. Use according to claim 1 or 2, characterized in that frankincense or a boswellic acid-containing vegetable extract is used.
4. Use according to claim 1 or 2, characterized by using a keto-boswellic acid, in particular 3-O-acetyl-11-keto- β -boswellic acid or 11-keto- β -boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative or a keto-boswellic acid-containing vegetable extract for the production of a medicament.
5. Use according to claim 1 or 2, characterized by using a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof for the production of a medicament.
6. Use according to any of claims 1 to 3, characterized by using an extract from the *Boswellia serrata* resin for the production of a medicament.
7. Use of the hydrogenation products of frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives

and the physiologically acceptable salts thereof, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative or a boswellic acid-containing vegetable preparation for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease.

8. Use according to claim 7, wherein the medicament is used for preventing and/or treating Alzheimer's disease.

9. Use according to claim 7 or 8, characterized by using the hydrogenation product of a boswellic acid-containing vegetable extract.

10. Use according to claim 7 or 8, characterized by using a hydrogenated extract from the *Boswellia serrata* resin for the production of a medicament.

11. Use according to claim 7 or 8, characterized by using the hydrogenation product of boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative thereof, a salt of a boswellic acid derivative or a boswellic acid-containing vegetable preparation.

12. Use according to any of claims 7 to 11, wherein the hydrogenation product is dihydroboswellic acid.

13. Use according to claim 7 or 8, characterized in that the hydrogenation product is selected from the group consisting of β -dihydroboswellic acid acetate, β -dihydroboswellic acid formate, β -dihydroboswellic acid methyl ester, acetyl- β -dihydroboswellic acid, α -dihydroboswellic acid, acetyl- α -dihydroboswellic acid and formyl- α -dihydroboswellic acid.

14. Use according to claim 7 or 8, characterized by using a keto-dihydroboswellic acid, in particular acetyl-11-keto- β -dihydroboswellic acid, 11-keto- β -

dihydroboswellic acid or formyl-11-keto- β -dihydroboswellic acid, a physiologically acceptable salt of a keto-dihydroboswellic acid, a derivative of a keto-dihydroboswellic acid, a salt of a keto-dihydroboswellic acid derivative or a hydrogenated keto-boswellic acid-containing vegetable extract for the production of the medicament.

15. Use according to claim 7 or 8, characterized by using a hydrogenation product of tirucallic acid, its salt or a derivative thereof or a hydrogenated tirucallic acid-containing vegetable extract for the production of the medicament.

16. Use according to any of claims 1 to 15, characterized in that the medicament is made for the intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

17. Use according to any of claims 1 to 16, characterized in that the medicament is available as a tablet or solution.